Literature DB >> 304783

Influence of SRBC/lymphocyte ratio on T-cell rosettes in alcoholic liver disease and inflammatory bowel disease.

M G Mutchnick, D S White, A C Dopp.   

Abstract

Thymus-derived (T) rosette-forming cells were enumerated in patients with alcoholic liver disease and in patients with inflammatory bowel disease using variable sheep red blood cell (SRBC)/lymphocyte ratios. SRBC/lymphocyte ratios of 60:1 and 32:1 did not reveal significant differences from controls in Crohn's disease. The percentage, but not absolute count, of T cells was significantly reduced in alcoholic hepatitis at the 60:1 ratio. Both the percentage and absolute count of T cells were reduced in alcoholic hepatitis and Crohn's disease with the 8:1 ratio. No significant reduction in T cells was seen at any ratio in patients with compensated alcoholic cirrhosis or ulcerative colitis. Use of a SRBC/lymphocyte ratio of 8:1 indentifies T cells which demonstrate an avidity for SRBC. This avidity may be related to the density of SRBC receptors on the surface of T cells and/or the affinity of these receptor sites for SRBC. Use of the 8:1 ratio may provide a more sensitive means by which to monitor changes in T-cell rosettes in patients suspected of having an altered cellular immune state.

Entities:  

Mesh:

Year:  1977        PMID: 304783      PMCID: PMC1541124     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  Binding of sheep erythrocytes to human lymphocytes. A probable marker of T lymphocytes.

Authors:  S S Fröland
Journal:  Scand J Immunol       Date:  1972       Impact factor: 3.487

2.  Peripheral blood T and B cells in chronic inflammatory bowel disease.

Authors:  R G Strickland; S Korsmeyer; R D Soltis; I D Wilson; R C Williams
Journal:  Gastroenterology       Date:  1974-10       Impact factor: 22.682

3.  Technical aspects of the rosette tests used to detect human complement receptor (B) and sheep erythrocyte-binding (T) lymphocytes.

Authors:  N F Mendes; M E Tolnai; N P Silveira; R B Gilbertsen; R S Metzgar
Journal:  J Immunol       Date:  1973-09       Impact factor: 5.422

4.  Age-related variation in proportion of circulating T cells.

Authors:  M A Smith; J Evans; C M Steel
Journal:  Lancet       Date:  1974-10-19       Impact factor: 79.321

5.  Reduction in circulating T lymphocytes in alcoholic liver disease.

Authors:  I M Bernstein; K H Webster; R C Williams; R G Strickland
Journal:  Lancet       Date:  1974-08-31       Impact factor: 79.321

6.  Anergy to dinitrochlorobenzene and depression of T-lymphocytes in Crohn's disease and ulcerative colitis.

Authors:  S Meyers; D B Sacher; R N Taub; H D Janowitz
Journal:  Gut       Date:  1976-11       Impact factor: 23.059

7.  Peripheral blood lymphocyte populations in chronic liver disease.

Authors:  H C Thomas; M Freni; J Sanchez-Tapias; D de Villiers; S Jain; S Sherlock
Journal:  Clin Exp Immunol       Date:  1976-11       Impact factor: 4.330

8.  Localization of T and B cells and alpha fetoprotein in hepatic biopsies from patients with liver disease.

Authors:  G Husby; R G Strickland; J L Caldwell; R C Williams
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808

9.  The human rosette-forming cell as a marker of a population of thymus-derived cells.

Authors:  J Wybran; M C Carr; H H Fudenberg
Journal:  J Clin Invest       Date:  1972-10       Impact factor: 14.808

10.  Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells.

Authors:  M Jondal; G Holm; H Wigzell
Journal:  J Exp Med       Date:  1972-08-01       Impact factor: 14.307

View more
  1 in total

1.  Studies on isolated gut mucosal lymphocytes in inflammatory bowel disease. Detection of activated T cells and enhanced proliferation to Staphylococcus aureus and lipopolysaccharides.

Authors:  C Fiocchi; J R Battisto; R G Farmer
Journal:  Dig Dis Sci       Date:  1981-08       Impact factor: 3.199

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.